DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 19-787/S-027

Pfizer Inc.
Attention: Mr. Robert Clark
235 East 42nd Street
New York, NY 10017

Dear Mr. Clark:

Please refer to your supplemental new drug application dated October 2, 2003 submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Norvasc (amlodipine besylate) 2.5, 5 and 10 mg Tablets.

We acknowledge receipt of your submission dated October 3, 2003.

Your submission of October 3, 2003 constituted a complete response to our March 7, 2003 action letter.

This supplemental new drug application provides for electronic final printed labeling revised as follows:

1. The following paragraph has been added to the section **CLINICAL PHARMACOLOGY/Studies in patients with Congestive Heart Failure** :

   Another study (PRAISE-2) randomized patients with NYHA class III (80%) or IV (20%) heart failure without clinical symptoms or objective evidence of underlying ischemic disease, on stable doses of ACE inhibitor (99%), digitalis (99%) and diuretics (99%), to placebo (N=827) or Norvasc (N=827) and followed them for a mean of 33 months. There was no statistically significant difference between NORVASC and placebo in the primary endpoint of all-cause mortality (95% confidence limits from 8% reduction to 29% increase on NORVASC). With NORVASC there were more reports of pulmonary edema.

2. In the **ADVERSE REACTION** section, "pulmonary edema" has been removed since it is fully described in the **CLINICAL PHARMACOLOGY/Studies in Patients with Congestive Heart Failure** section of the package insert**.**

We have completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on October 3, 2003.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call Ms. Denise M. Hinton, Regulatory Health Project Manager, at (301) 594-5333.

Sincerely,

{See appended electronic signature page}
Douglas C. Throckmorton, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Doug Throckmorton
12/3/03 08:12:04 AM